Perception of airway narrowing in a general population sample

C.M. Salome*, W. Xuan**, E.J. Gray*, E. Belooussova**, J.K. Peat*


ABSTRACT: In epidemiological studies, defining asthma as the presence of airway hyperresponsiveness (AHR) plus recent symptoms leaves two groups of subjects whose clinical significance is unclear: those with asymptomatic AHR, and those with symptoms only. The aim of the study was to determine whether subjects with symptoms only differ from the normal and asthmatic groups in the perception of airway obstruction.

Six hundred and ninety seven adults completed a questionnaire of symptoms and underwent bronchial challenge with histamine to induce airway obstruction. Recent symptoms included wheeze and morning chest tightness in the last 12 months. AHR was defined as a provoking dose of histamine causing ≥20% fall in forced expiratory volume in one second (PD20FEV1) <3.9 µmol. At the end of the challenge test, subjects who felt wheezy or tight in the chest marked a value from 0 to 10 on a modified Borg scale, to describe the severity of the sensation.

Subjects with asymptomatic AHR did not differ significantly from subjects with AHR plus recent symptoms (current asthma) either in the mean fall in FEV1 or in the median Borg score. In subjects with symptoms only, the mean Borg score was not significantly different from that of the asthmatic subjects, although mean fall in FEV1 differed significantly (p<0.0001). In subjects with symptoms only, chest tightness correlated significantly with the fall in forced vital capacity (FVC) (p=0.011), but not with the fall in FEV1.

Subjects with asymptomatic airways hyperresponsiveness were not poor perceivers of airway narrowing, but may underreport their symptoms. Subjects with symptoms only may have enhanced perception of small changes in lung function, particularly in forced vital capacity. Eur Respir J 1997; 10: 1052–1058.

Asthma is characterized by variable airway narrowing, which is usually indicated clinically as the presence of episodic wheeze or chest tightness. There have been many epidemiological studies of the prevalence of asthma using questionnaires which ask about the occurrence and frequency of these symptoms [1]. The problem with using symptom-based questionnaires is that people vary in their perception of airway narrowing, so that for any given fall in lung function there is a wide range of perceived chest tightness [2]. Thus, for some subjects, sensations of wheeze or chest tightness may be associated with changes in lung function that are of little clinical relevance or, alternatively, marked changes in lung function may not be perceived at all.

For epidemiological studies in adults and children, we define current asthma as the presence both of airway hyperresponsiveness (AHR) and recent symptoms [3–6]. In children, this definition distinguishes a group with ongoing, clinically relevant airway disease [4, 7]. However, AHR and symptoms can occur independently and, in any population, there are significant numbers of subjects with asymptomatic AHR, and subjects with symptoms without evidence of AHR. Whilst there are a number of alternative explanations, it is possible that the presence or absence of reported symptoms in these subjects is due to differences in their ability to perceive changes in lung function. Brand et al. [8] suggest that subjects with asymptomatic AHR do not report symptoms because they are poor perceivers of airway narrowing. However, there have been no studies of perception of symptoms in subjects with a history of wheeze or chest tightness, without AHR.

The aim of this study was to determine whether adults from a general population sample, classified according to airway responsiveness and recent symptoms, differ in their perception of airway narrowing induced by bronchial provocation with histamine. In particular, we wished to examine the hypothesis that subjects with asymptomatic AHR are poor perceivers, while those with symptoms, but no AHR, are hyperperceivers of the sensation of chest tightness or wheeze.

Methods

Population

The study was conducted in Wagga Wagga, an inland rural town in southern New South Wales. The methods of population selection and the characteristics of the
population have been reported in detail previously [6].
In July 1992, a large random sample of 8–11 year old
children attending schools in the area were recruited for
a separate study of asthma prevalence. In October 1992,
a letter was sent to the home address of the adults liv-
ing in the same homes as these children, inviting them
to participate in the current study. All adults in the house-
hold were asked to complete a questionnaire and then
attend a location in the town centre for lung function
and allergy tests. Follow-up phone calls were made to
arrange appointments. A telephone survey of a random
selection of 305 refusers and nonattenders showed that
4% had used an asthma medication in the last month,
compared to 8% of attenders (p<0.05). Among the attend-
ers, there were more females than males (p<0.001). These
differences suggest that females and subjects with recent
asthma were more likely to attend.

Questionnaire

The questionnaire was a shortened version of the Inter-
national Union Against Tuberculosis and Lung Disease
(IUATLD) questionnaire [9], and comprised questions of
recent and past respiratory symptoms, including occupa-
tional symptoms, family history, diagnosed asthma and
medication use, and hospital and doctor attendances.
Subjects who reported wheeze, wheeze following ex-
ercise, chest tightness on waking, or shortness of breath
coming on at rest, which had occurred in the previous
12 months, were classified as having "recent symptoms".

Histamine challenge

A bronchial challenge test with histamine was admi-
nistered to all subjects with baseline forced expiratory
volume in one second (FEV1) ≥60% predicted, using the
rapid method [10]. Lung function was recorded by dry
rolling-seal spirometers (Mijnhardt BV, Bunnick, Hol-
land) connected to IBM-PC computers running Scienti-
fic and Medical software for immediate data acquisition.
Forced expiratory manoeuvres were repeated until two
readings of FEV1 and forced vital capacity (FVC) with-
in 100 mL were obtained, the largest of which was used
in analyses. Values for FEV1 and FVC were recorded as
a percentage of the predicted values of Knudson et
al. [11]. Subjects who had taken short-acting β-agonist
or anticholinergic aerosols within 6 h of presenting were
asked to withhold medication before returning for later
testing. Long-acting β-agonist aerosols were not available
in Australia at the time of this study. Histamine diphos-
phate (BDH, UK) was administered using DeVilbiss No.
45 handheld nebulizers (DeVilbiss Co., Somerset, PA,
USA), in doubling doses from 0.03–3.9 µmol. The test
was stopped if the FEV1 fell by 20% or more. Salbutamol
aerosol was administered to aid recovery when neces-
sary.

Subjects in whom a ≤3.9 µmol dose of histamine pro-
voked a 20% fall in FEV1 (PD20FEV1 ≤3.9 µmol) were
classified as having AHR. Dose-response ratio (DRR)
was calculated for all subjects as the percentage fall in
FEV1 at the last dose, divided by the total dose admin-
istered [12]. Because many subjects had an FEV1 which
remained stable or improved slightly during bronchial
challenge, and thus gave a zero or negative value, a con-
stant of 3 was added to all DRR values to obtain a posi-
tive value for logarithmic conversion [5, 13], so that they
are indicated by the units % fall·µmol⁻¹ + 3.

Four subjects who presented with FEV1 <60% pred
did not undergo histamine challenge, and their data are
not included in the present report.

Borg scores

As soon as the bronchial challenge test was complet-
ed, the operator who had carried out the test asked each
subject a standard question: "Did you feel wheezy or
tight in the chest during the test?" If the subject answered
yes, they were asked a second question: "Have you felt
like that before?" Subjects were then asked to describe
the severity of the sensation they experienced during
the challenge by marking a value on a modified Borg
scale [2]. The modified Borg scale extends from 0 to 10,
with 0 marked "Not at all" and 10 marked "Extremely
severe", and simple descriptors, such as "Slight", "Mod-
erate" or "Very severe" at intervening numbers. Specific
questions about wheeze or chest tightness were asked
in order to exclude symptoms of upper airway or throat
irritation.

Allergic sensitization

Sensitization to common allergens was measured by
the reaction to a skin-prick test to the forearm [14]. The
eight allergens tested were: house dust; house dust mites
(Dermatophagoides pteronyssinus and D. farinae); cat
dander; ryegrass; plantain; Alternaria tenuis; and cock-
roach. Histamine and glycerol were used as positive and
negative controls. After 15 min, wheal size was recor-
ded as the long axis and its perpendicular; mean wheal
size was used in analyses. A reaction was regarded as
positive if the wheal size was ≥4 mm. Subjects were
considered atopic if they had a positive reaction to any
of the allergens tested.

Definitions

On the basis of data from the questionnaire and bron-
chial challenge, subjects were classified into four groups:
1) "Normal", no AHR and no symptoms in the last 12
months; 2) "Symptoms only", no AHR, but symptoms in
the last 12 months; 3) "Asymptomatic AHR", PD20FEV1
<3.9 µmol, no symptoms in the last 12 months; 4)
"Current Asthma", PD20FEV1 <3.9 µmol, symptoms in
the last 12 months. For the purposes of this classifica-
tion, symptoms included wheeze, wheeze following ex-
ercise, chest tightness on waking, or shortness of breath
coming on at rest.

Statistical analysis

Data were analysed using the Statistical Analysis Sys-
tem (SAS) software package (SAS Institute Inc., Cary,
NC, USA). Geometric mean values are reported for
DRR values, which were transformed to base 10 logarithms before analysis. Mean values are given with the 95% confidence intervals (95% CI). Confidence intervals for proportions close to the extreme were calculated using the formula of Fleiss [15], in order to avoid confidence intervals outside the possible range. Median values, and the interquartile range, are given for the Borg scores. Chi-squared analyses were used to determine associations between categorical variables, and unpaired t-tests were used for continuous, normally-distributed variables. Spearman’s rank correlation coefficients were calculated to examine the association between Borg score and the lung function variables. Comparisons of Borg scores between groups were made using the Kruskal-Wallis test for multiple comparisons and the Wilcoxon signed ranks test for two group comparisons. Analysis of variance (ANOVA) using Duncan’s post-hoc test was used to assess differences in lung function between the four groups. A p-value of less than 0.05 was considered significant.

Logistic regression was used to determine the factors associated with experiencing wheeze or chest tightness during the challenge test. Spearman’s correlation coefficients were used to determine which variables were associated with magnitude of the Borg score in subjects who experienced chest tightness and wheezing during the challenge. A stepwise procedure, using partial correlation coefficients, was used to determine which variables were independently associated with the Borg score.

**Results**

It was estimated that the group of adults who attended for testing comprised 62% of the sample base. Of the 697 adults (aged 18–73 yrs) who underwent challenge testing with histamine, 74% were classified as normal (having neither AHR nor recent symptoms), 6% had current asthma (with both AHR and recent symptoms), 18% had symptoms only, and 3% had asymptomatic AHR. Table 1 shows the characteristics of the four groups. They did not differ significantly in mean age, in the proportion of current and ex-smokers, or in gender ratio, although males were underrepresented in all groups. Mean DRR differed significantly between all groups, and both atopy and abnormal baseline lung function, defined as FEV1/FVC ratio <75%, were more common in the two groups with AHR. The percentage of subjects in each group who experienced symptoms of wheeze or chest tightness during the bronchial challenge test is shown in table 2. Most of the subjects with current asthma experienced symptoms, whilst relatively few of the normal subjects felt wheeze or chest tightness. Of the subjects with asymptomatic AHR, 86% felt wheeze or chest tightness during the challenge, and two thirds of these had experienced these feelings before. More than half of the “Symptoms only” group experienced wheeze or chest tightness during challenge, and 92% of these had felt the sensation before.

**Table 1. – Characteristics of subject groups classified on the basis of symptom history, the questionnaire, and AHR to histamine**

<table>
<thead>
<tr>
<th></th>
<th>Normal</th>
<th>Symptoms only</th>
<th>Asymptomatic AHR</th>
<th>Asthma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjects n</td>
<td>512</td>
<td>124</td>
<td>22</td>
<td>39</td>
</tr>
<tr>
<td>Male %</td>
<td>44</td>
<td>40</td>
<td>40</td>
<td>46</td>
</tr>
<tr>
<td>Mean age yrs</td>
<td>38 (38–39)</td>
<td>38 (37–39)</td>
<td>40 (36–44)</td>
<td>37 (35–38)</td>
</tr>
<tr>
<td>Atopic %</td>
<td>43 (39–47)</td>
<td>59 (50–68)</td>
<td>86 (64–96)</td>
<td>92 (78–98)</td>
</tr>
<tr>
<td>Current smokers %</td>
<td>18 (14–21)</td>
<td>25 (17–33)</td>
<td>18 (2–34)</td>
<td>26 (12–39)</td>
</tr>
<tr>
<td>Ex-smokers %</td>
<td>28 (24–32)</td>
<td>25 (17–33)</td>
<td>27 (9–46)</td>
<td>23 (10–36)</td>
</tr>
<tr>
<td>FEV1 % pred</td>
<td>102 (101–103)</td>
<td>98 (95–101)</td>
<td>97 (92–101)</td>
<td>92 (87–96)</td>
</tr>
<tr>
<td>FVC % pred</td>
<td>98 (98–100)</td>
<td>96 (94–99)</td>
<td>98 (95–102)</td>
<td>97 (92–102)</td>
</tr>
<tr>
<td>Abnormal lung function %</td>
<td>3 (1–4)</td>
<td>10 (5–16)</td>
<td>27 (9–46)</td>
<td>36 (21–51)</td>
</tr>
<tr>
<td>Mean DRR % fall·µmol⁻¹ + 3</td>
<td>3.9 (3.8–4.0)</td>
<td>4.7 (4.5–5.0)</td>
<td>11.6 (9.9–13.7)</td>
<td>30.2 (20.0–45.8)</td>
</tr>
</tbody>
</table>

Values are either percentage of subject group or means, with 95% confidence intervals in parentheses. Abnormal lung function and dose response ratio (DRR) are defined in the text. AHR: airway hyperresponsiveness; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; % pred: percentage of predicted value.

**Table 2. – Number of subjects who felt symptoms of wheeze or chest tightness during bronchial challenge with histamine, the percentage who had felt these symptoms before, and the mean falls (Δ) in lung function during bronchial challenge in those subjects**

<table>
<thead>
<tr>
<th></th>
<th>Normal</th>
<th>Symptoms only</th>
<th>Asymptomatic AHR</th>
<th>Asthma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjects n</td>
<td>127</td>
<td>67</td>
<td>19</td>
<td>35</td>
</tr>
<tr>
<td>% of subject group</td>
<td>25 (21–29)</td>
<td>54 (45–63)</td>
<td>86 (64–96)</td>
<td>89 (75–97)</td>
</tr>
<tr>
<td>Felt that way before %</td>
<td>47 (35–56)</td>
<td>92 (81–97)</td>
<td>68 (43–86)</td>
<td>94 (79–99)</td>
</tr>
<tr>
<td>Median Borg score</td>
<td>2 (3)</td>
<td>3 (3)</td>
<td>4 (2)</td>
<td>4 (3)</td>
</tr>
<tr>
<td>p-value#</td>
<td>0.003</td>
<td>0.0006</td>
<td>0.005</td>
<td></td>
</tr>
<tr>
<td>ΔFEV1 %</td>
<td>6.6 (6–7)</td>
<td>9.3 (8–10)</td>
<td>24.3 (23–26)</td>
<td>27.3 (25–29)</td>
</tr>
<tr>
<td>p-value#</td>
<td>0.0006</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
<tr>
<td>ΔFVC %</td>
<td>4.8 (4–6)</td>
<td>7.2 (6–8)</td>
<td>18.1 (15–21)</td>
<td>21.0 (18–24)</td>
</tr>
<tr>
<td>p-value#</td>
<td>0.0055</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
</tbody>
</table>

Values in parentheses are 95% confidence intervals (95% CI), with the exception of the severity scores for wheeze or chest tightness which are shown as medians and interquartile range (IQR) in parenthesis. #: compared with the normal group. For definitions see legend to table 1.
Atopy, AHR, recent wheeze, current use of asthma medication, and smoking history (current or past smoking) were significant risk factors for the occurrence of wheeze or tightness during the challenge. The odds ratios, adjusted for each of these factors, are shown in figure 1. In the Normal group, the occurrence of wheeze or tightness during the challenge was significantly associated both with atopy (Chi-squared=9.62; p<0.01) and with smoking history (Chi-squared 13.24; p<0.001). These associations were not significant in the group with symptoms only.

The median Borg scores and the mean falls in FEV1 and FVC in those subjects who experienced symptoms during the challenge are shown in table 2. In the Normal group, the median Borg score, indicating the severity of wheeze or chest tightness during the challenge, differed significantly from that in the other three groups (p=0.0008). Subjects with asymptomatic AHR did not differ significantly from subjects with current asthma either in the mean fall in FEV1 or in the median Borg score at the end of the challenge. In subjects with symptoms only, the median Borg score was not significantly different from that of the asthmatic subjects (p=0.65), despite a large difference in the mean fall in FEV1 (9 vs 27%; p<0.0001).

Normal subjects and those with symptoms only, by definition, had falls in FEV1 during the bronchial challenge test which were less than 20%. However, many of these subjects experienced wheeze or chest tightness during the test. Those who reported such sensations had significantly greater falls in FEV1 and FVC than those who did not feel wheeze or chest tightness (table 3). Borg score was significantly correlated with change in FEV1 (Spearman’s ρ=0.33; p<0.0001) and FVC (ρ=0.35; p<0.0001). Despite this significant correlation, fall in FEV1 explained only 8% of the variation in Borg score, and, for any given fall in FEV1, there was a wide range of perceived severity. In the subjects with symptoms only, Borg score correlated with the fall in FVC (p=0.33; p=0.0078), but not with the fall in FEV1 (p=0.19; p=0.12) (fig. 2). In the other three subject groups, there were no significant correlations between Borg score and change in lung function. In the two groups with AHR, there was no significant correlation between Borg score and DRR

---

**Table 3.** – Falls (Δ) in FEV1 and FVC in the subjects without AHR who felt wheeze or chest tightness, and in those who did not feel wheeze or chest tightness during the challenge

<table>
<thead>
<tr>
<th>Subjects with wheeze or chest tightness</th>
<th>Subjects without wheeze or chest tightness</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subjects n</td>
<td>127</td>
<td>385</td>
</tr>
<tr>
<td>ΔFEV1 %</td>
<td>(6–8)</td>
<td>(3–4)</td>
</tr>
<tr>
<td>ΔFVC %</td>
<td>(4–6)</td>
<td>(2–3)</td>
</tr>
<tr>
<td>Symptoms only</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subjects n</td>
<td>67</td>
<td>57</td>
</tr>
<tr>
<td>ΔFEV1 %</td>
<td>(8–10)</td>
<td>(4–6)</td>
</tr>
<tr>
<td>ΔFVC %</td>
<td>(6–8)</td>
<td>(3–6)</td>
</tr>
</tbody>
</table>

Values are presented as means, and 95% confidence intervals in parentheses. For definitions see legend to table 1.
Partial correlation coefficients were used to determine which factors were independently associated with severity of wheeze and chest tightness. In the group as a whole, two factors were significantly associated with Borg score: percentage fall in FVC ($\rho=0.35; p=0.0001$) and current use of asthma medication ($\rho=0.14; p=0.027$). Once these factors were accounted for, no further variation in Borg score was associated with dose response ratio, percentage fall in FEV\textsubscript{1}, baseline FEV\textsubscript{1}, baseline FVC, baseline FEV\textsubscript{1}/FVC ratio, or age. Similar analyses using only data from the groups without AHR, that is the Normal and Symptoms only groups, produced a model which included three factors: percentage fall in FVC ($\rho=0.30; p=0.0001$), current use of asthma medication ($\rho=0.21; p=0.0045$), and baseline FVC ($\rho=0.17; p=0.019$).

Discussion

This study has shown that, in this population of adults, wheeze and chest tightness induced by bronchial challenge with histamine were related to changes in FEV\textsubscript{1} and FVC, but these changes explained only a small portion of the variation in symptom severity. Almost all of the subjects with asymptomatic AHR experienced wheeze or chest tightness during the bronchial challenge, and many recognized the sensation as one they had experienced previously. The severity of the sensation was not significantly different from that experienced by subjects with current asthma. These findings suggest that subjects with asymptomatic AHR are not poor perceivers of airway narrowing, but that they may underreport their symptoms. On the other hand, subjects with recent symptoms but no AHR to histamine appeared to have a heightened sensation of small changes in lung function induced by histamine. The severity of wheeze and chest tightness in these subjects was similar to that experienced by the asthmatic subjects, despite the fact that their change in lung function was considerably smaller than in the asthmatic subjects.

In this study, standard methods with established reliability were used to classify the subjects according to their airway responsiveness and recent symptoms. We used a well-established method for the histamine challenge [10], and a shortened version of the standard IUATLD questionnaire [9]. Asthma was defined as the presence of AHR and recent symptoms of wheeze, wheeze with exercise, chest tightness on waking, or shortness of breath coming on at rest. This definition discriminates asthma symptoms and identifies the group with the most severe impairment [4, 7]. Although the response rate was low, and only just adequate for estimates of prevalence, comparisons between groups of change in lung function and of Borg scores are likely to be reliable. There was a slightly higher rate of attenders with recent asthma, increasing the numbers in the symptomatic groups, but this is unlikely to introduce any bias into the measurements of sensation or lung function change in these groups. The number of subjects in the group with asymptomatic AHR was small, and this is reflected in the larger confidence intervals for the symptom scores and change in lung function in this group. However, the sample size was sufficient to show that the measurements in this group differed significantly from the Normal group.

The modified Borg scale, used in this study to measure the severity of perceived wheeze or chest tightness, has been used in other studies of spontaneous and induced airway narrowing [2, 8, 16]. In this study, a single measurement was made at the end of challenge, when the subjects were asked to rate the severity of the sensations they experienced during the challenge test. This technique differs from that used in other studies, where Borg scores have been measured before and after challenge, allowing the association between change in lung function and change in sensation to be estimated. In the present study, we wished to exclude sensations in the upper airway or throat caused by the irritant effect of histamine, and focus on sensations in the lower airways. To do this, we avoided asking an open-ended question about any symptoms the subjects may have experienced, and asked specifically about wheeze or chest tightness, sensations which could be attributed to the lower airways.

Subjects with asymptomatic AHR had Borg scores which were not different from those of the asthmatic subjects, suggesting that they were not poor perceivers of acute airway narrowing. This finding is consistent with that of Gibson et al. [17], who also found that children with asymptomatic AHR to methacholine experienced symptoms during the challenge. On the other hand, the present findings differ from those of Brand et al. [8], who suggest that asymptomatic AHR is associated with reduced perception of airway narrowing. However, there are substantial differences in methodology between the present study and that of Brand et al. [8], whose study population included subjects with much milder AHR, and who used the Borg score before and after challenge to measure change in breathlessness. The measurements were made at ≥10% fall in FEV\textsubscript{1}, rather than at ≥20% fall as in the present study, and were analysed as a dichotomous (change/no change) variable.

It is likely that many subjects with asymptomatic AHR underreport their symptoms. Two thirds of the subjects with asymptomatic AHR recognized the sensation of wheeze or chest tightness induced by the challenge as something that they had experienced previously. In the questionnaire, subjects were asked to report symptoms that had occurred within the last 12 months. It seems likely that some underreporting would occur over such a long recall period, particularly if the symptoms were mild or infrequent. The mean DRR values in the group with asymptomatic AHR were only just in the abnormal range [5], suggesting that the airway abnormality in this group is mild. In other studies, asymptomatic AHR has been associated with increased risk of symptoms at a later date [18, 19], and with increased peak expiratory flow (PEF) variability [17], suggesting that these subjects may have very mild or unrecognized asthma.

Alternatively, subjects with asymptomatic AHR may have a different airway pathology from that found in asthma. In the present study, one third of the group with asymptomatic AHR did not recognize the sensation of chest tightness or wheeze, and presumably had no prior experience of such symptoms. Gibson et al. [17] also
found that few of their children with asymptomatic AHR recognized the symptoms induced by methacholine challenge as something they had experienced previously. In children with asymptomatic AHR, the number of eosinophils in induced sputum does not differ from that in normal children [20], suggesting that airway inflammation is a not a feature of the pathology. It has been suggested that the sensation of bronchoconstriction is enhanced by the presence of airway inflammation [21], and that the absence of symptoms in subjects with asymptomatic AHR may be due to the absence of airway inflammation [17]. Airway hyperresponsiveness in the absence of airway inflammation may reflect some other abnormality of airway geometry or structure.

Subjects with asymptomatic AHR had less severe AHR than the current asthma group, and thus received a larger total dose of histamine during the challenge procedure. However, it seems unlikely that the higher doses of histamine had a direct effect on sensation in these subjects, since there was no correlation between DRR and Borg score in the hyperresponsive groups. This is consistent with the findings of Brand et al. [8], who also found no correlation between perception scores and AHR.

Subjects with recent symptoms, but no AHR, perceived the sensation of bronchoconstriction with a similar severity to that of the asthmatic subjects, even though they had a much smaller fall in FEV1 during challenge. It is not clear if these subjects have asthma or any other significant airway problem. Almost 51% of the Symptoms only group had experienced symptoms which were severe enough to have required bronchodilator medications in the last 12 months. Current medication was a significant factor in the model predicting Borg score, suggesting that those subjects with symptoms severe enough to require treatment tended to record the highest Borg scores, independently of the magnitude of the change in lung function.

Since treatment with inhaled corticosteroids can reduce AHR in people with current symptoms [22], it could be argued that subjects with recent symptoms, but no AHR, may have lost their AHR as a result of corticosteroid therapy. However, only 14% of the Symptoms only group had taken inhaled corticosteroids in the 12 months prior to testing, suggesting that such treatment is unlikely to account for the absence of AHR in most of this group.

Alternatively, AHR may be absent in subjects with episodic, seasonal asthma, if they are tested out of season [23]. In the Symptoms only group, there were significantly more atopic subjects, and more pollen atopic subjects than in the Normal group (44 vs 23%), suggesting that some may have been at risk of seasonal symptoms. The studies were conducted in October, spring in the southern hemisphere, when pollen levels were likely to be at their highest, and thus pollen sensitive subjects would be more likely to have AHR at this time. Atopy was a significant risk factor for the occurrence of wheeze or chest tightness during the challenge test in the group as a whole; however, there was no significant association when the Symptoms only group was considered separately.

More than half of the subjects in the Symptoms only group reported feeling chest tightness during the challenge, and almost all of these had felt this sensation before. In these subjects, the fall in FEV1 was small compared to that in the subjects with AHR, suggesting that they may be hyperperceivers of small changes in lung function. In asthmatic subjects, recent evidence suggests that breathlessness during induced obstruction is closely related to airway closure and hyperinflation. Lougheed et al. [16] have shown that change in respiratory capacity explains 20.6% of variation in Borg score during challenge with methacholine and 19.4% during bronchodilation. In the present study, fall in FVC was the factor most strongly associated with Borg score. In the Symptoms only group, the severity of histamine-induced symptoms correlated with change in FVC during the challenge, but not with change in FEV1. Although the mean fall in FVC was only 7%, these data suggest that, in this group of subjects, airway closure and hyperinflation may be a determinant of symptoms during challenge.

A small proportion of normal subjects felt chest tightness or wheeze during the challenge, but less than half of these recognized the sensation as something they had felt before. In the Normal group, those who felt chest-tightness had greater falls in lung function than those who did not, and the occurrence of symptoms during the challenge was strongly associated with a history of smoking and, to a lesser extent, with atopy. In some normal subjects, smoking and atopy may enhance the response of the airways to histamine, so that these subjects are able to perceive the small changes in lung function which occur during challenge. In subjects with AHR, Brand et al. [8] did not find any association between smoking and change in Borg score after challenge.

The definition of asthma depends, in part, on the ability of subjects to report their symptoms. In this study, we have shown that many subjects are able to perceive changes in lung function, which may be quite small. However, subjects vary widely, not only in the perceived severity of lung function changes, but also in the likelihood that such changes will be reported as symptoms. Further studies are needed to evaluate the prognostic significance of symptoms which occur in the absence of airways hyperresponsiveness, and to determine whether such symptoms are associated with airway inflammation.

Acknowledgements: The authors acknowledge the financial support of Allen and Hanburys, the National Health and Medical Research Council of Australia, the Asthma Foundation of NSW and the Community Health and Anti-Tuberculosis Association. They also thank the Wagga Wagga branch of the Asthma Foundation of NSW, for help in organizing the study, and the research assistants who helped to collect the data.

References
3. Salome CM, Peat JK, Britton WJ, Woolcock AJ. Bronchial responsiveness in two populations of Australian